Blockade of OX40-OX40L Interactions Attenuates Allograft Rejection Mediated by CD4 T Cells That Recognize Alloantigen through the Direct but Not Indirect Pathway of Allorecognition

Blockade of OX40-OX40L Interactions Attenuates Allograft Rejection Mediated by CD4 T Cells That Recognize Alloantigen through the Direct but Not Indirect Pathway of Allorecognition

Detalhes bibliográficos
Principais autores:	Kinnear, G, Wood, K, Fallah-Arani, F, Jones, N
Formato:	Conference item
Publicado em:	2012

Registros relacionados

A diametric role for OX40 in the response of effector/memory CD4+ T cells and regulatory T cells to alloantigen.
por: Kinnear, G, et al.
Publicado em: (2013)

Role of OX40-OX40L interactions in the immune response to solid organ allografts
por: Kinnear, G
Publicado em: (2013)

Anti-OX40 prevents effector T-cell accumulation and CD8+ T-cell mediated skin allograft rejection.
por: Kinnear, G, et al.
Publicado em: (2010)

An OX-Tra’Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis
por: Kaviyon Sadrolashrafi, et al.
Publicado em: (2024-03-01)

Uptake of HLA Alloantigens via CD89 and CD206 Does Not Enhance Antigen Presentation by Indirect Allorecognition
por: Eytan Breman, et al.
Publicado em: (2016-01-01)

Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes
por: Ayaka Sato, et al.
Publicado em: (2025-01-01)

Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia
por: Dawei Cui, et al.
Publicado em: (2019-01-01)

OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis.
por: Gwyer Findlay, E, et al.
Publicado em: (2014)

Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis
por: Xiaoling Zhou, et al.
Publicado em: (2022-01-01)

OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab
por: Ana Maria Lé, et al.
Publicado em: (2022-12-01)

OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand.
por: al-Shamkhani, A, et al.
Publicado em: (1996)

Roquin recognizes a non-canonical hexaloop structure in the 3′-UTR of Ox40
por: Robert Janowski, et al.
Publicado em: (2016-03-01)

Research progress on OX40/OX40L axis mediated T cell immunity in the course of oral lichen planus
por: LIU Yang, et al.
Publicado em: (2022-07-01)

699 A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models
por: Bo Zhang, et al.
Publicado em: (2020-11-01)

Mast Cell-Derived Exosomes Promote Th2 Cell Differentiation via OX40L-OX40 Ligation
por: Fei Li, et al.
Publicado em: (2016-01-01)

Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma
por: Xianlong Chen, et al.
Publicado em: (2022-07-01)

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
por: Peixin Chen, et al.
Publicado em: (2021-11-01)

Breaking Immunological Tolerance through OX40 (CD134)
por: Pratima Bansal-Pakala, et al.
Publicado em: (2001-01-01)

OX40L/OX40 Signal Promotes IL-9 Production by Mucosal MAIT Cells During Helicobacter pylori Infection
por: Siqi Ming, et al.
Publicado em: (2021-03-01)

OX40-OX40L interaction promotes proliferation and activation of lymphocytes via NFATc1 in ApoE-deficient mice.
por: Jinchuan Yan, et al.
Publicado em: (2013-01-01)

Development of OX40 agonists for canine cancer immunotherapy
por: Damien Ruiz, et al.
Publicado em: (2022-10-01)

CD40-CD40 ligand-independent activation of CD8+ T cells can trigger allograft rejection.
por: Jones, N, et al.
Publicado em: (2000)

CD40-CD40L independent activation of CD8+T cells can trigger allograft rejection.
por: Jones, N, et al.
Publicado em: (2000)

A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab
por: Asaad Abdelhalim, et al.
Publicado em: (2024-11-01)

Relationship between bladder cancer and polymorphisms of OX40 (rs17568) and OX40L (rs1234313) genes in a Turkish population
por: Osman Bilen, et al.
Publicado em: (2023-03-01)

Enhancement of the Soluble Form of OX40 and OX40L Costimulatory Molecules but Reduction of the Membrane Form in Type 1 Diabetes (T1D)
por: Jingnan An, et al.
Publicado em: (2019-01-01)

Lymphatic Reconstruction in Kidney Allograft Aggravates Chronic Rejection by Promoting Alloantigen Presentation
por: Jinwen Lin, et al.
Publicado em: (2021-12-01)

Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
por: William L Redmond, et al.
Publicado em: (2012-01-01)

Ox-LDL increases OX40L in endothelial cells through a LOX-1-dependent mechanism
por: Q. Dong, et al.
Publicado em: (2013-09-01)

OX40 is required for regulatory T cell-mediated control of colitis.
por: Griseri, T, et al.
Publicado em: (2010)

OX40 facilitates control of a persistent virus infection.
por: Tobias Boettler, et al.
Publicado em: (2012-09-01)

OX40 agonists and combination immunotherapy: putting the pedal to the metal
por: Stefanie N Linch, et al.
Publicado em: (2015-02-01)

Tissue specific deletion of inhibitor of kappa B kinase 2 with OX40-Cre reveals the unanticipated expression from the OX40 locus in skin epidermis.
por: Georgina H Cornish, et al.
Publicado em: (2012-01-01)

Corrigendum: Lymphatic reconstruction in kidney allograft aggravates chronic rejection by promoting alloantigen presentation
por: Jinwen Lin, et al.
Publicado em: (2022-11-01)

OX40 stimulation enhances protective immune responses induced after vaccination with attenuated malaria parasites
por: Othman, A, et al.
Publicado em: (2018)

OX40 Stimulation Enhances Protective Immune Responses Induced After Vaccination With Attenuated Malaria Parasites
por: Ahmad Syibli Othman, et al.
Publicado em: (2018-07-01)

Affinity and kinetics of the interaction between soluble trimeric OX40 ligand, a member of the tumor necrosis factor superfamily, and its receptor OX40 on activated T cells.
por: Al-Shamkhani, A, et al.
Publicado em: (1997)

Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade.
por: Brook, M, et al.
Publicado em: (2005)

Association of OX40L gene polymorphism with multiple sclerosis in Iranians
por: Abdolreza Sotoodeh Jahromi, et al.
Publicado em: (2024-03-01)

Structural Basis of a Novel Agonistic Anti-OX40 Antibody
por: Jing Zhang, et al.
Publicado em: (2022-08-01)